Current Status and Future Directions for Immunotherapy in Hepatocellular Carcinoma

Download All
Learn how to leverage immune checkpoint inhibitors for optimal management of HCC across different settings with expert-authored slides and an on-demand Webcast capturing a dynamic, live CCO Webinar.
Ghassan K. Abou-Alfa, MD, MBA
Program Director
Peter R. Galle, MD, PhD
Bruno Sangro, MD, PhD

On-Demand Webcast

Get up to date on how European experts leverage immune checkpoint inhibitor–based therapy to optimally treat patients with early-stage through metastatic hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD, MBA
Program Director
Peter R. Galle, MD, PhD Bruno Sangro, MD, PhD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: October 26, 2020 Expired: No longer available for credit
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings